BioNTech Reviews

Recent deployment of capital has lacked strategic value and vision (I.e., Kite manufacturing site acquisition, Instadeep acquisition, BioNTainer project, Object Oriented Organization design, to name a few). If/how any of these examples will add value to patients, investors, or the company is unclear. Internal communication around company strategy and concrete plans to achieve that strategy/vision is virtually nonexistent to employees. Cash burn rate is alarmingly high given the public revenue projections, lack of late stage assets with no impending near-term launches, no existing commercial capabilities or presence in the world’s largest market. Existing capital will need to bridge until the company can find additional revenue streams. This is a German company that has operations in other countries, not a global company. There is a big difference. Leaders outside of Germany have little to no empowerment, regardless of position or experience. There are some minor cons that are not dissimilar to the majority of other companies in our industry (i.e., high workload, changing priorities, and grueling ambitions). The largest differentiating cons at BioNTech (and the primary reason that I left) is the top level executives (mainly CEO) are grossly unequipped and unable to bring the company to the next level. There is zero experience at the top level for successfully leading a global company in bringing multiple drugs to market. Unfortunately, the self awareness of this by CEO is nonexistent, overshadowed by hubris, ego, and his unwavering need to control everything. I hesitate to leave such a harsh review for one of the primary individuals responsible for saving countless lives through his genius in discovering the construct upon which the COVID vaccine was developed upon. This is not meant to come across as unappreciative for these scientific and public health contributions. I consider myself very fortunate to have had the opportunity to be a part of BioNTech during these past few years. However, that genius does not translate to aptitude for leading a 5,000+ employee company across multiple countries and regions. CEO continues to operate the company as he operates his labs, by forming his own hypotheses and experimenting with the company. There are countless examples of founder CEOs that struggle to evolve as their companies evolve. What will it take for BioNTech to recognize that what got the company to where it is today, will not get the company where it wants to go in the future? *Disclaimer* the content of this review are my own personal opinions and views and are not meant to represent any views or opinions on behalf of the company or it’s affiliates.

they treated the contracted (to hire) employees as if they were not actually a part of the team, something I had not experienced before with this type of contact work. There were multiple contracted employees in this position so it was not a person to person basis. Additionally supervisors and lower level management of this team continued to assure us they were doing all they could to give us the same small benefits that non contacted employees had, and trying to include us in those small things. For instance we were not given any company T-Shirts and other small favors as part of our introduction week, and there was a welcome talk where new hire names were mentioned and asked to introduce themselves, except for ours. We worked on multiple important projects for them over our months working there. Our supervisor completely lied to us about the security of our contracts, consistently having performance meetings with us and assured us we were on track for being hired at the end of the contract. Instead of letting us know they decided to end the contract, we were told nothing, only for all of the contracted employees to get the same call from the contract agency to ask if we were aware our contracts had been terminated. i have NEVER felt this disrespectful as a contract worker